NASDAQ:NLNK NewLink Genetics (NLNK) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$1.48▼$1.9050-Day Range$0.89▼$14.1052-Week Range$0.82▼$3.60Volume107,070 shsAverage Volume547,540 shsMarket Capitalization$67.19 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisCompetitorsTrendsStock AnalysisCompetitorsTrends Get NewLink Genetics alerts: Email Address Ad American Hartford Gold GroupPrepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.GET THE FREE GUIDE About NewLink Genetics Stock (NASDAQ:NLNK)NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma. The company also develops NLG207 in combination with paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer; NLG802, a prodrug of indoximod, which has completed Phase I clinical trial; and NLG919, a direct enzymatic inhibitor. The company has collaboration and license agreement with Genentech Inc. for the development and commercialization of NLG919, as well as a research collaboration for the discovery of next generation IDO/TDO inhibitors; and Merck Sharpe & Dohme Corp. to research, develop, and commercialize rVSV G-ZEBOV GP, an Ebola vaccine product candidate. NewLink Genetics Corporation was founded in 1999 and is headquartered in Ames, Iowa.Read More Ad Traders Agencytop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.Click here now for the full details of this stock that’s set to rocket in the AI revolution… NLNK Stock News HeadlinesMay 17, 2024 | cnet.comBest DNA Test for 2024May 15, 2024 | markets.businessinsider.comNewLink Genetics is about to announce earnings — here's what Wall Street expectsJuly 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.March 20, 2024 | wsj.comNewlink Technology Inc.March 6, 2024 | markets.businessinsider.comHere's what Wall Street expects from NewLink Genetics's earnings reportDecember 19, 2023 | investing.comNewlink Technology Inc (9600)October 27, 2023 | foxnews.comSuicide and genetics: Study identifies 12 DNA variations that could increase the riskAugust 23, 2023 | forbes.comGenetic Testing Before Pregnancy: What You Need To KnowJuly 26, 2024 | Crypto 101 Media (Ad)Brace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range. But that could change soon. Very soon.June 28, 2023 | thestreet.comWhy NewLink Genetics (NLNK) Stock Is Gaining TodayMay 23, 2023 | fool.comDigimarc (NASDAQ: DMRC)February 15, 2023 | thestreet.comTrade Ebola Stocks? Sure, But Don't Bet on Big Business OpportunityJanuary 17, 2023 | dailymail.co.ukWill parents take up a DNA test to spot rare diseases? Expert predicts genetic codes of babies could be read by the NHS in as little as five yearsJanuary 14, 2023 | thestreet.comJumpstart ASCO '15 With This Quick List of Hot Research AbstractsJanuary 14, 2023 | thestreet.comCorbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed PositiveAugust 3, 2021 | markets.businessinsider.comHere's what Wall Street expects from NewLink Genetics's earningsSee More Headlines Receive NLNK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewLink Genetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2019Today7/26/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:NLNK CUSIP65151110 CIK1126234 Webwww.newlinkgenetics.com Phone515-296-5555FaxN/AEmployees55Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,990,000.00 Net Margins-4,592.84% Pretax MarginN/A Return on Equity-41.50% Return on Assets-33.95% Debt Debt-to-Equity RatioN/A Current Ratio7.98 Quick Ratio7.98 Sales & Book Value Annual Sales$940,000.00 Price / Sales61.15 Cash FlowN/A Price / Cash FlowN/A Book Value$2.11 per share Price / Book0.73Miscellaneous Outstanding Shares37,328,000Free FloatN/AMarket Cap$57.49 million OptionableNot Optionable Beta1.17 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Charles J. Link Jr. (Age 60)Co-Founder, Chairman, CEO & Chief Scientific Officer Mr. Nicholas N. Vahanian (Age 52)Co-Founder, Pres, Chief Medical Officer & Director Dr. Eugene P. Kennedy M.D. (Age 50)FACS, Chief Medical Officer Mr. Brian Wiley (Age 51)Chief Commercial Officer Mr. Carl W. Langren (Age 64)CFO & Principal Accounting Officer Key CompetitorsRigel PharmaceuticalsNASDAQ:RIGLAchieve Life SciencesNASDAQ:ACHVAgenusNASDAQ:AGENRegulus TherapeuticsNASDAQ:RGLSVerastemNASDAQ:VSTMView All Competitors NLNK Stock Analysis - Frequently Asked Questions How were NewLink Genetics' earnings last quarter? NewLink Genetics Corp (NASDAQ:NLNK) released its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($0.27) EPS for the quarter, hitting analysts' consensus estimates of ($0.27). The biotechnology company had revenue of $0.25 million for the quarter. NewLink Genetics had a negative net margin of 4,592.84% and a negative trailing twelve-month return on equity of 41.50%. What other stocks do shareholders of NewLink Genetics own? Based on aggregate information from My MarketBeat watchlists, some other companies that NewLink Genetics investors own include Inovio Pharmaceuticals (INO), Arbutus Biopharma (ABUS), OPKO Health (OPK), Novavax (NVAX), SunPower (SPWR), Synergy Pharmaceuticals (SGYP) and Sarepta Therapeutics (SRPT). This page (NASDAQ:NLNK) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewLink Genetics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share NewLink Genetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.